Abstract: [Object] Provided are a 11C-labeled acyclic retinoid that can be synthesized in a short time with a high yield and can be suitably used for PET for elucidating intracerebral kinetics, a PET probe using it, and methods for producing them. [Solution] The 11C-labeled acyclic retinoid of the present invention is characterized by being represented by the following chemical formula (a). This compound can be produced by a coupling step of cross-coupling a methyl iodide labelled with 11C and the following organotin compound (b) (provided that in the formula, R1 and R2 represent alkyl groups which may have a branch) in an aprotic solvent in the presence of a palladium complex, a phosphine ligand, and a cuprous halide.

Abstract: This invention relates to a kit or device for detection of hippocampal atrophy comprising a nucleic acid(s) capable of specifically binding to particular hippocampal atrophy marker miRNA(s) or to complementary strand(s) thereof, and a method for detecting hippocampal atrophy comprising measuring such miRNA(s) in vitro.

Abstract: The present invention provides a method for introducing substituents into the ?-position and the ?-position of an ?,?-unsaturated ketone, which not only can be used for the synthesis of a prostaglandin by a three-component coupling process, but also enables synthesis of a prostaglandin in a high yield by one-pot operation without requiring the use of a large excess amount of any of the three components required for the synthesis or using a highly toxic heavy metal as a catalyst or a solvent that is highly toxic to living bodies, and a method for synthesizing a prostaglandin using the same technical means.

Abstract: An object of the present invention is to solve problems in terms of stagnation of research on norovirus by providing a cultured transgenic cell or a transgenic animal in which murine norovirus (MNV) can be grown across the barrier of host specificity in mammalian cells, and providing a screening method that uses the cultured transgenic cell or the transgenic animal. The present inventors have found that MNV infection is determined in a cultured transgenic mammalian cell or a mammal possessing the cultured transgenic mammalian cell as its own cell, the cultured transgenic mammalian cell containing one or more species selected from the entirety or a portion of the murine CD300F gene and/or a CD300 family gene having an extracellular domain nucleotide sequence similar to that of the murine CD300F gene. The present inventors have solved the aforementioned problems by providing, for example, a norovirus-related drug screening method on the basis of this finding.

Abstract: Provided are a biomarker for evaluating a cerebral A? accumulation state using amyloid precursor protein (APP)-derived A? and A?-like peptides in a living body-derived sample as an index, and a method for analysis thereof. A marker for determining a cerebral A? accumulation state, the marker comprising a combination of at least two ratios selected from the group consisting of: a ratio of A?1-39 (SEQ ID NO.: 1) level to A?1-42 (SEQ ID NO.: 3) level: A?1-39/A?1-42; a ratio of A?1-40 (SEQ ID NO.: 2) level to A?1-42 (SEQ ID NO.: 3) level: A?1-40/A?1-42; and a ratio of APP669-711 (SEQ ID NO.: 4) level to A?1-42 (SEQ ID NO.: 3) level: APP669-711/A?1-42, in a living body-derived sample.

Abstract: Provided are a biomarker for evaluating a cerebral A? accumulation state using an amyloid precursor protein (APP)-derived peptide in a living body-derived sample as an index, and a method for analysis thereof. A living body-derived sample derived from a test subject is measured, and at least one ratio selected from the group consisting of APP669-711/APP672-713 (A?1-42); APP672-709 (A?1-38)/APP672-713 (A?1-42); APP674-711 (A?3-40)/APP672-713 (A?1-42); APP672-710 (A?1-39)/APP672-713 (A?1-42); APP672-711 (A?1-40)/APP672-713 (A?1-42); and APP672-711 (OxA?1-40)/APP672-713 (A?1-42) is calculated, and when each of the ratios of the test subject is higher than each of standard levels which are ratios of a person having normal cognitive function NC? who is negative for cerebral A? accumulation, an accumulation amount of cerebral A? of the test subject is determined as larger than an accumulation amount of cerebral A? of the person having normal cognitive function NC?.

Abstract: An object of the invention is to provide an 11C-labeled catechol derivative having sufficient radioactivity to obtain an imaging image by a PET apparatus, a PET probe of a phosphorylated tau aggregation inhibitor using the same, and a method for producing them. The 11C-labeled catechol derivative of the present invention is represented by the following general formula (a) (wherein R is a substituent having an isopropylamino group, and the carbon at the 2-position of the isopropylamino group is labeled with 11C).

Abstract: The present invention provides a method for introducing substituents into the ?-position and the ?-position of an ?,?-unsaturated ketone, which not only can be used for the synthesis of a prostaglandin by a three-component coupling process, but also enables synthesis of a prostaglandin in a high yield by one-pot operation without requiring the use of a large excess amount of any of the three components required for the synthesis or using a highly toxic heavy metal as a catalyst or a solvent that is highly toxic to living bodies, and a method for synthesizing a prostaglandin using the same technical means.

Abstract: An object of the invention is to provide an 11C-labeled catechol derivative having sufficient radioactivity to obtain an imaging image by a PET apparatus, a PET probe of a phosphorylated tau aggregation inhibitor using the same, and a method for producing them. The 11C-labeled catechol derivative of the present invention is represented by the following general formula (a) (wherein R is a substituent having an isopropylamino group, and the carbon at the 2-position of the isopropylamino group is labeled with 11C).

Abstract: An object of the invention is to provide a 11C-labeled O6-benzylguanine capable of obtaining a PET image and a process for producing the same. The 11C-labeled O6-benzylguanine of the invention is represented by the following chemical formula (a). The 11C-labeled O6-benzylguanine is produced by: a coupling step of cross-coupling a methyl iodide labeled with 11C and the following organotin compound (b) (R1 represents an alkyl group, and R2 and R3 represent a leaving group which can be eliminated with a base) in the presence of a palladium complex, a phosphine ligand, and cuprous halide in an aprotic lactam; and a desorption step of desorbing the leaving groups R2 and R3 of the coupling product obtained by the coupling step with a base.

Abstract: An embodiment according to the present invention provides a kit or device for detection of dementia, and a method for detecting dementia. An embodiment according to the present invention relates to: a kit or device for detection of dementia, including a nucleic acid(s) capable of specifically binding to an miRNA(s) or a complementary strand(s) thereof in a sample from a subject; and a method for detecting dementia, including measuring the miRNA(s) in vitro.

Abstract: Provided is a dental pretreatment material for dental tissue regeneration by use of dental pulp stem cells, particularly a dental pretreatment material effectively enabling dental tissue regeneration even by use of dental pulp stem cells of middle-aged or older individuals. The dental pretreatment material is characterized by comprising a serine protease, specifically trypsin. The dental pretreatment material comprising trypsin is used as an injection into a root canal before a root canal filling material comprising dental pulp stem cells and an extracellular matrix is inserted into the root canal as an attempt to regenerate a dental pulp and a dentin. The root canal filling material includes an ALK5 inhibitor, a CCR3 antagonist, or a CCL11 neutralizing antibody.

Abstract: An amyloid fibril formation inhibitor comprising a compound represented by the following general formulae (I) to (III): wherein Q is —C(?O)—; X is —C(?O)—, —NH—C(?O)—; Y is —(CH2)m—; Z is —(CH2)n—; R1, R2, and R3 are each independently a hydrogen atom, an alkyl group, a hydroxyalkyl group, an alkylaminoalkyl group; and R4 is an amino group, an alkylamino group or the like; or a pharmaceutically acceptable salt thereof or a solvate thereof.

Abstract: An aerobic exercise assistance apparatus 1 includes an input/output unit 131 that, under control by a control unit, gives a user a question and accepts an input of an answer from the user to the question while the user performs the aerobic exercise. The control unit controls the load application driving unit 110, 120 to change the load applied by the load application driving unit 110, 120, based on a correct answer ratio of the user for the question and timing of the answer to the question by the user.

Abstract: The present invention provides a tau protein aggregation inhibitor. In addition, a therapeutic agent or a preventive agent for tauopathy, including a tau protein aggregation inhibitor, and a method for screening for a tau protein aggregation inhibitor, are also provided. The problems are solved by a tau protein aggregation inhibitor including a fluorone dye or a pharmaceutically acceptable salt thereof. Moreover, the problems are also solved by a method for screening a tau protein aggregation inhibitor, wherein the method includes: (1) a step of preparing transgenic Drosophila that express a human tau protein in neurons, (2) a step of administering a candidate compound to the transgenic Drosophila, and (3) a step of measuring the motor function of the transgenic Drosophila that have been administered with the candidate compound in the step (2).

Abstract: An object of the invention is to provide a 11C-labeled O6-benzylguanine capable of obtaining a PET image and a process for producing the same. The 11C-labeled O6-benzylguanine of the invention is represented by the following chemical formula (a). The 11C-labeled O6-benzylguanine is produced by: a coupling step of cross-coupling a methyl iodide labeled with 11C and the following organotin compound (b) (R1 represents an alkyl group, and R2 and R3 represent a leaving group which can be eliminated with a base.) in the presence of a palladium complex, a phosphine ligand, and cuprous halide in an aprotic lactam; and a desorption step of desorbing the leaving groups R2 and R3 of the coupling product obtained by the coupling step with a base.

Abstract: A suction drain device of a disclosed liquid collecting apparatus actively pushes and pulls blood. This achieves liquid collection at high speed even under decreased pressure depending on a physiological state of an animal. Moreover, the liquid collecting apparatus includes a first flow path and a second flow path having a given length. Accordingly, the flow path with a given length set in advance and thus a known volume allows collection of a given amount volume of blood without measuring a length and an amount of blood using a volume measuring device. Accordingly, no need of the measuring device allows reduction in size of the liquid collecting apparatus. Consequently, the liquid collecting apparatus can be installed adjacent to the animal to achieve reduction in dead volume. Moreover, blood is flown to a fourth flow path branched with a connecting terminal, and is also flown to the second flow path branched with a connecting terminal.

Abstract: A method and an apparatus for measuring and displaying dental plaque are provided, and the method includes the steps of dividing near infrared light output from a light source into measurement light and reference light, applying the measurement light toward a tooth in an oral cavity and scanning the tooth with the measurement light, producing interference light from reflected light and back-scattered light from the tooth and the reference light, generating an optical coherence tomographic image based on a scattering intensity value of the interference light, extracting a dental plaque region having a specific scattering intensity value from the optical coherence tomographic image, and quantifying the dental plaque. A method and an apparatus for measuring and displaying gingiva and/or alveolar bone are further provided. A method and an apparatus for quantifying dental plaque, digitizing the dental plaque, and generating an image of the dental plaque in a noncontact, noninvasive manner are thereby provided.

Abstract: An object of the present invention is to solve problems in terms of stagnation of research on norovirus by providing a cultured transgenic cell or a transgenic animal in which murine norovirus (MNV) can be grown across the barrier of host specificity in mammalian cells, and providing a screening method that uses the cultured transgenic cell or the transgenic animal. The present inventors have found that MNV infection is determined in a cultured transgenic mammalian cell or a mammal possessing the cultured transgenic mammalian cell as its own cell, the cultured transgenic mammalian cell containing one or more species selected from the entirety or a portion of the murine CD300F gene and/or a CD300 family gene having an extracellular domain nucleotide sequence similar to that of the murine CD300F gene. The present inventors have solved the aforementioned problems by providing, for example, a norovirus-related drug screening method on the basis of this finding.

Abstract: Provided are a biomarker for evaluating a cerebral A? accumulation state using amyloid precursor protein (APP)-derived A? and A?-like peptides in a living body-derived sample as an index, and a method for analysis thereof. A marker for determining a cerebral A? accumulation state, the marker comprising a combination of at least two ratios selected from the group consisting of: a ratio of A?1-39 (SEQ ID NO.: 1) level to A?1-42 (SEQ ID NO.: 3) level: A?1-39/A?1-42; a ratio of A?1-40 (SEQ ID NO.: 2) level to A?1-42 (SEQ ID NO.: 3) level: A?1-40/A?1-42; and a ratio of APP669-711 (SEQ ID NO.: 4) level to A?1-42 (SEQ ID NO.: 3) level: APP669-711/A?1-42, in a living body-derived sample.